Meibomian Gland Dysfunction Clinical Trial
Official title:
Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction
The investigators hypothesize that the dry eye caused by SS may include the evaporative type, resulting from the MGD. Furthermore, the investigators hypothesize that both pSS and sSS are associated with MGD.To test our hypothesis, we conducted a prospective clinical study in patients with SS (both pSS and sSS) and MGD, and the normal population All subjects were matched for both age and gender and assessed for tear function and ocular surface signs and symptoms.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | June 30, 2018 |
Est. primary completion date | May 31, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 45 Years to 60 Years |
Eligibility |
Inclusion Criteria: - All the subjects are female and age between 50-60 years - Patients with primary SS fulfilled the criteria established by the European Study Group - Patients with SLE and RA met the criteria set by the American College of Rheumatology Exclusion Criteria: - The control history of autoimmune disease |
Country | Name | City | State |
---|---|---|---|
China | Lanzhou University Second Hospital | Lanzhou | Gansu |
Lead Sponsor | Collaborator |
---|---|
LanZhou University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ocular Surface Disease Index | The OSDI questionnaire is used to quantify the dry eye symptoms. Subjects will be asked questions regarding the dry eye symptoms that they had experienced; the OSDI questions is drawn from 3 different subscales: ocular symptoms, vision-related functions, and environmental triggers. Each answer is scored on a 4-point scale from zero (indicating no problems) to four (indicating a significant problem). Responses to all of the questions are combined to generate a composite OSDI score that ranges from 0 to 100, with higher OSDI scores indicating more severe symptoms. Symptoms of dry eye, such as dryness, burning, foreign body sensation, stabbing pain, photophobia, and visual fluctuations, are also noted | up to 3 months after tear substitutes apply | |
Primary | meibomian gland function | assessment of the quality of meibomian gland secretions, according to a published classification system (21). In brief, the grading scheme was "0" for clear excreta with small particles, "1" for opaque excreta with normal viscosity, "2" for opaque excreta with increased viscosity, and "3" for secreta that retained shape after digital expression. | up to 3 months after tear substitutes apply | |
Primary | fluorescein staining of the cornea | Upper, lower, nasal, temporal and central quadrants were used. Superficial punctate keratopathy (SPK) in the cornea was scored from 0 to 3 in each quadrant: 0, no staining in the cornea; 1, <5 punctuate stains; 2, >5 punctuate stains but <10; and 3, >10 or filamentous staining detected. The total number was obtained by adding the scores of the four quadrants for each eye (0-15). | up to 3 months after tear substitutes apply | |
Primary | noninvasive tear breakup time | Four IR diodes were set on the Keratograph 5 (Oculus, Wetzlar, Germany) and arranged in two pairs, located one above the other. The red ring illumination used for corneal topography was deactivated; this ensured a dark background for the examination. An illuminated ring pattern was then projected onto the cornea. At the start of the recording, the subject will be asked to blink his or her eyes three times and then to keep them open as long as possible. Irregularities in the reflected image will be observed closely. Special attention will be given to distortions and gaps in individual rings and the time such deviations from the original ring pattern took to occur. The examination will be recorded on video. | up to 3 months after tear substitutes apply | |
Primary | Schirmer's test with and without anesthesia | The Schirmer test without anesthesia (S1T) for tear secretion function will be performed by inserting a 30-mm Schirmer tear test strip (Jingming, Tianjing, China) into the inferior fornix at the junction of the middle and lateral thirds of the lower eyelid margin. Schirmer test strips will remain in place for 5 minutes with the eyes closed. The extent of wetting will be subsequently measured according to the scale provided by the manufacturer. Potential scores ranged from 0 to 30 mm, with lower scores indicating greater tear production abnormalities. | up to 3 months after tear substitutes apply | |
Secondary | tear meniscus | The subject will be asked to blink her eyes once ,then the image of tear meniscus height will be captured by a Keratograph 5 (Oculus, Wetzlar, Germany).After that tear meniscus height will be measured at the centre of the lower lid margin. This performance will be taken three times and the average value will be recorded. | up to 3 months after tear substitutes apply | |
Secondary | rose bengal staining of the conjunctiva | rose bengal staining (graded on a 0-3 scale) of the conjunctiva (six nasal and temporal areas) and the whole cornea. | up to 3 months after tear substitutes apply |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT04884243 -
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Terminated |
NCT02596919 -
Fast Infrared Meibography (Photography)
|
N/A | |
Completed |
NCT01207752 -
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT06064071 -
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
|
N/A | |
Completed |
NCT03652051 -
A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
|
Phase 2 | |
Recruiting |
NCT03767530 -
Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Active, not recruiting |
NCT05577910 -
Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD
|
N/A | |
Completed |
NCT04889950 -
Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
|
N/A | |
Recruiting |
NCT06004895 -
Mechanisms of Light-based Therapies for Dry Eye Disease
|
N/A | |
Completed |
NCT04147962 -
Intense Pulsed Light in Meibomian Gland Dysfunctions
|
||
Completed |
NCT02256969 -
Intraductal Meibomian Gland Probing Trial
|
Phase 4 | |
Recruiting |
NCT05089591 -
Intense Pulsed Light in Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT04500821 -
Evaluation of the LipiFlow System With a New Activator
|
N/A | |
Completed |
NCT03318874 -
Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction
|
Phase 4 | |
Completed |
NCT06278584 -
iLux Treatment for Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04052841 -
Morphological Analysis of Meibomian Glands
|
N/A | |
Completed |
NCT05028491 -
The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients
|